{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:36:22Z","timestamp":1792985782403,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmoop.2024.103699","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T17:55:55Z","timestamp":1725904555000},"page":"103699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-2092","authenticated-orcid":false,"given":"M.","family":"Vaz Batista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garrig\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4382-4726","authenticated-orcid":false,"given":"M.","family":"Fern\u00e1ndez-Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5084-2746","authenticated-orcid":false,"given":"A.","family":"Mart\u00ednez-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-6562","authenticated-orcid":false,"given":"I.","family":"Teruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fernandez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Servitja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de la Haba-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1691-1849","authenticated-orcid":false,"given":"J.","family":"P\u00e9rez-Escuredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-1346","authenticated-orcid":false,"given":"D.","family":"Alcal\u00e1-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sampayo-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-0391","authenticated-orcid":false,"given":"A.","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2024.103699_bib1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103699_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103699_bib3","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/2159-8290.CD-22-0703","article-title":"Navigating the HER2-low paradigm in breast oncology: new standards, future horizons","volume":"12","author":"Tarantino","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103699_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103699_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","article-title":"Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases","volume":"29","author":"Kabraji","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103699_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10371","key":"10.1016\/j.esmoop.2024.103699_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"10390","key":"10.1016\/j.esmoop.2024.103699_bib8","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103699_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103699_bib10","series-title":"Basking Ridge","year":"2022"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103699_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"34","key":"10.1016\/j.esmoop.2024.103699_bib12","first-page":"S334","article-title":"A\u00a0pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03","author":"Hurvitz","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103699_bib13","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103699_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2024.103699_bib15","first-page":"S88","article-title":"260P - Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial","volume":"33","author":"Epaillard","year":"2022","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103699_bib16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jnci\/djr238","article-title":"More randomization in phase II trials: necessary but not sufficient","volume":"103","author":"Rubinstein","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103699_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103699_bib18","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1002\/onco.13830","article-title":"Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial","volume":"26","author":"Hurvitz","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103699_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103699_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102324","article-title":"Targeting brain metastases in breast cancer","volume":"103","author":"Corti","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2024.103699_bib21","doi-asserted-by":"crossref","unstructured":"Harbeck N, Modi S, Jacot W, et\u00a0al. Trastuzumab deruxtecan vs treatment of physician\u2019s choice in patients with HER2-low unresectable and\/or metastatic breast cancer: subgroup analyses from DESTINY-Breast04. Abstract P1-11-01. Presented at 2022 San Antonio Breast Cancer Symposium.","DOI":"10.1158\/1538-7445.SABCS22-P1-11-01"},{"key":"10.1016\/j.esmoop.2024.103699_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/EDBK_175338","article-title":"Breast cancer in the central nervous system: multidisciplinary considerations and management","volume":"37","author":"Lin","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 9","key":"10.1016\/j.esmoop.2024.103699_bib25","article-title":"Abstract PO2-10-06: An open-label interventional, multicenter study of trastuzumab deruxtecan monotherapy in patients with unresectable and\/or metastatic HER2-Low or HER2 immunohistochemistry 0 breast cancer: DESTINY-Breast15","volume":"84","author":"Modi","year":"2024","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103699_bib26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"33","key":"10.1016\/j.esmoop.2024.103699_bib28","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: american society of clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103699_bib29","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S1470-2045(17)30693-9","article-title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","volume":"19","author":"Camidge","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:35:40Z","timestamp":1727379340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2059702924014686"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103699","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103699"}}